Menu
 
Research menu
Jump to menu

Publications:  Dr Michelle Lockley

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al.(2020). Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448] (Gynecologic Oncology (2019) 154(2) (441–448), (S0090825819311813), (10.1016/j.ygyno.2019.04.679)). Gynecologic Oncology vol. 157, (2) 558-559.
10.1016/j.ygyno.2020.02.023
Berney DM, Shamash J, Stoneham S, Lockley M(2020). Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Eur J Cancer vol. 130, 267-268.
10.1016/j.ejca.2020.02.003
Casey L, Powell A, Bohm S, Manchanda R, Lockley M, Kobel M, Singh N (2020). Role of Ki67 Proliferation Index and CD8 Tumour-Infitrating Lymphocyte Counts in Predicting Outcome in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC) Showing No/Partial Response to Neoadjuvant Chemotherapy. MODERN PATHOLOGY. vol. 33, 1024-1024.
McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L et al.(2020). Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. Int J Gynecol Cancer vol. 30, (2) 221-226.
10.1136/ijgc-2019-000630
Berney DM, Stoneham S, Arora R, Shamash J, Lockley M(2020). Ovarian germ cell tumour classification: views from the testis. Histopathology vol. 76, (1) 25-36.
10.1111/his.14016
https://qmro.qmul.ac.uk/xmlui/handle/123456789/68085
Wood GE, Lockley M, Kermorgant S (2019). 68PC-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer. Annals of Oncology. vol. 30,
10.1093/annonc/mdz413.072
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley L-A et al. (2019). COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA. CLINICAL CANCER RESEARCH. vol. 25, 64-64.
Hockings H, Wood G, Lockley M (2019). EP870 Bevacizumab facilitates surgery in previously inoperable patients with low-grade serous ovarian cancer: a case series. International Journal of Gynecological Cancer. vol. 29,
10.1136/ijgc-2019-esgo.918
Hockings HA, Mossner M, Lakatos E, Graham T, Lockley M (2019). Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer. Annals of Oncology. vol. 30,
10.1093/annonc/mdz413.030
https://qmro.qmul.ac.uk/xmlui/handle/123456789/68004
Heath O (2019). The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63550
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker S-J, Lockley M(2019). GCT-30 Surgical management of ovarian germ cell tumours. European Urology Supplements vol. 18, (4)
10.1016/s1569-9056(19)32497-2
Shamash J, Ansell W, Alifrangis C, Sahdev A, Thomas B, Wilson P, Mazhar D, Warren A et al.(2019). GCT-84 The impact of a supranetwork-multidisciplinary team (SMDT) on decision making in testicular cancers: A ten-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). European Urology Supplements vol. 18, (4)
10.1016/s1569-9056(19)32551-5
Heath OM, Maniati E, Belato C, Gopinathan G, Lecker L, Lakhani A, Pegrum C, McDermott J et al. (2019). Abstract 1103: The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastases. 1103-1103.
10.1158/1538-7445.am2019-1103
Saxena J, Nicolini F, Lockley M (2019). Abstract 3801: Reversing chemoresistance in high grade serous ovarian cancer. 3801-3801.
10.1158/1538-7445.sabcs18-3801
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S et al.(2019). Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology
10.1016/j.ygyno.2019.04.679
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58607
Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker SJ, Ledermann J et al.(2019). A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. European Journal of Cancer vol. 113, 19-27.
10.1016/j.ejca.2019.03.001
https://qmro.qmul.ac.uk/xmlui/handle/123456789/59100
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al.(2019). Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (British Journal of Cancer, (2017), 116, 10, (1294-1301), 10.1038/bjc.2017.86). British Journal of Cancer vol. 120, (8)
10.1038/s41416-019-0433-6
Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L(2019). Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet vol. 56, (3) 195-198.
10.1136/jmedgenet-2017-105140
Lockley M, Stoneham SJ, Olson TA(2019). Ovarian cancer in adolescents and young adults. Pediatr Blood Cancer vol. 66, (3)
10.1002/pbc.27512
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56192
Böhm S, Le N, Lockley M, Brockbank E, Faruqi A, Said I, Jeyarajah A, Wuntakal R et al.(2019). Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. Int J Gynecol Cancer
10.1136/ijgc-2018-000092
Lockley M, Newton C, Murali K, Ahmed A, Hockings H, Berney D, Shamash J, Banerjee S et al. (2018). A multicentre analysis of malignant ovarian germ cell tumours: rationale for alignment of paediatric and adult practice and for chemotherapy de-escalation in specific subtypes. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. vol. 28, 42-43.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/66613
Wood GE, Heuss SF, Osagie I, Lockley M, Kermorgant S (2018). c-Met signalling and endocytosis in clear cell ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. vol. 28, 95-95.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/66688
Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA et al.(2018). Copy number signatures and mutational processes in ovarian carcinoma. Nature Genetics vol. 50, (9) 1262-1270.
10.1038/s41588-018-0179-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/59041
Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M (2018). Abstract A54: Generation and characterization of a novel panel of platinum-resistant HGSOC models. a54-a54.
10.1158/1557-3265.ovca17-a54
Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al. (2018). Abstract PR14: CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma. pr14-pr14.
10.1158/1557-3265.ovca17-pr14
Walton J, Farquharson M, Mason S, Blagih J, Ennis D, Leung E, Dowson S, Athineos D et al. (2018). CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high-grade serous carcinoma. CLINICAL CANCER RESEARCH. vol. 24, 36-37.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/66691
Hoare JI, Saxena J, Hockings H, McDermott J, Browne A, Lockley M (2018). Generation and characterization of a novel panel of platinum-resistant HGSOC models. CLINICAL CANCER RESEARCH. vol. 24, 68-68.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/66744
Devlin M-J, Chandrasekaran D, Singh N, Ledermann JA, Lockley M, McCormack M, Wilkinson N, Miller R et al.(2018). Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease. Journal of Clinical Oncology vol. 36, (15_suppl) 5581-5581.
10.1200/jco.2018.36.15_suppl.5581
https://qmro.qmul.ac.uk/xmlui/handle/123456789/66686
Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y et al.(2018). PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer. Cell Reports vol. 22, (9) 2469-2481.
10.1016/j.celrep.2018.02.028
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56422
Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al.(2017). Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov
10.1158/2159-8290.CD-17-0284
https://qmro.qmul.ac.uk/xmlui/handle/123456789/30984
Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ et al.(2017). A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology vol. 71, (5) 736-742.
10.1111/his.13272
McDermott JR, Jones R, Lockley M, Balkwill FR (2017). The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous Carcinoma. JOURNAL OF PATHOLOGY. vol. 243, S15-S15.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/61449
Walton J, Blagih J, Farquharson M, Ennis D, Leung E, Dowson S, Tookman LA, Orange C et al. (2017). Abstract AP24: CRISPR/CAS9–MEDIATED TRP53 , BRCA1 , BRCA2 AND PTEN KNOCKOUT TO GENERATE IMPROVED MURINE MODELS OF OVARIAN HIGH GRADE SEROUS CARCINOMA. ap24-ap24.
10.1158/1557-3265.ovcasymp16-ap24
Glasspool RM, Blagden SP, Lockley M, Paul J, Hopkins C, Thomson F, Brown J, Fernandes R et al.(2017). A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours. Journal of Clinical Oncology vol. 35, (15_suppl) 2594-2594.
10.1200/jco.2017.35.15_suppl.2594
Goranova T, Ennis D, Piskorz AM, MacIntyre G, Lewsley LA, Stobo J, Wilson C, Kay D et al.(2017). Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma - Experience of the BriTROC consortium. British Journal of Cancer vol. 116, (10) 1294-1301.
10.1038/bjc.2017.86
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39063
Ganesan R, Singh N, Casey L, Tam S, Farugi A, Prasad R, Boehm S, Lockley M et al. (2017). Immunohistochemical Expression of p53 and WT1 Is Retained Following Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma (HGSC). LABORATORY INVESTIGATION. vol. 97, 286A-287A.
La Russa M, Kokka F, Lockley M, Brockbank E(2016). Haemorrhagic shock due to spontaneous splenic rupture in a patient subsequently diagnosed with advanced ovarian cancer. J Obstet Gynaecol vol. 37, (2) 268-270.
10.1080/01443615.2016.1244811
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19027
Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C et al.(2016). CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research
10.1158/0008-5472.CAN-16-1272
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25148
Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH et al.(2016). A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clinical Cancer Research
10.1158/1078-0432.CCR-16-0081
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13383
BALKWILL F, Anne Montfort, Oliver Pearce(2016). Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research
10.1158/1078-0432.CCR-15-2657
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13991
Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D et al.(2016). Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer. b53-b53.
10.1158/1557-3265.ovca15-b53
Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M et al.(2016). RAD51 and BRCA2 enhance oncolytic adenovirus type 5 activity in ovarian cancer. Molecular Cancer Research vol. 14, (1) 44-55.
10.1158/1541-7786.MCR-15-0188-T
Montfort A, Boehm S, Dowe T, Topping J, Lockley M, Capasso M, Balkwill F (2015). Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastases. 455-455.
10.1158/1538-7445.am2015-455
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D et al.(2015). Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. J Clin Oncol vol. 33, (22) 2457-2463.
10.1200/JCO.2014.60.5212
Browne A, Tookman LA, Ingemarsdotter CK, Bouwman RD, Pirlo K, Wang Y, McNeish IA, Lockley M(2015). Pharmacological inhibition of β<inf>3</inf> integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity. Cancer Research vol. 75, (14) 2811-2821.
10.1158/0008-5472.CAN-14-3761
Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EYL et al.(2015). Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology vol. 9, (4) 791-805.
10.1016/j.molonc.2014.12.007
Browne AK, Tookman LA, Ingemarsdotter CK, Bouwman R, Pirlo K, Wang Y, Hodivala-Dilke KM, McNeish IA et al. (2014). 106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancer. European Journal of Cancer. vol. 50,
10.1016/s0959-8049(14)70232-1
Spurrell EL, Lockley M(2014). Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience vol. 8,
10.3332/ecancer.2014.441
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6573
Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T et al.(2013). Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB J vol. 27, (10) 4244-4253.
10.1096/fj.13-230441
Boehm S, Ennis D, Dowe T, Canosa M, McNeish I, Lockley M, Balkwill F (2013). Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patients. EUROPEAN JOURNAL OF CANCER. vol. 49, S736-S736.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7136
Rockall AG, Avril NE, Lam R, Mozley PD, Iannone R, Lockley M, Parkinson C, McNeish IA et al. (2013). [18F]Fluorodeoxyglucose PET and Volumetric CT analysis are early biomarkers of survival in platinum-sensitive relapsed ovarian cancer - a multicentre trial. EUROPEAN JOURNAL OF CANCER. vol. 49, S735-S735.
Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ et al.(2012). Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther vol. 20, (9) 1676-1688.
10.1038/mt.2012.116
Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D et al.(2012). The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol vol. 227, (2) 136-145.
10.1002/path.4002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13856
Schultes BC, Lolkema MPJK, Chu CL, Zhou H, Long A, Lockley M, Avery W, Kurtagic E et al. (2012). M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer. JOURNAL OF CLINICAL ONCOLOGY. vol. 30,
Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP et al.(2012). Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. PANCREATOLOGY vol. 12, (1) 8-15.
10.1016/j.pan.2011.12.009
Connell CM, Shibata A, Tookman L, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al.(2011). Genomic DNA damage and ATR-Chk1 signalling determine adenovirus oncolytic efficacy in ovarian cancer. HUMAN GENE THERAPY vol. 22, (10) A113-A113.
Connell CM, Shibata A, Tookman LA, Archibald KM, Flak MB, Pirlo KJ, Lockley M, Wheatley SP et al.(2011). Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. J Clin Invest vol. 121, (4) 1283-1297.
10.1172/JCI43976
Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA(2011). Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Mol Ther vol. 19, (3) 490-499.
10.1038/mt.2010.247
Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP et al.(2010). p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Mol Cancer vol. 9,
10.1186/1476-4598-9-175
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13470
Salako MA, Connell CM, Shibata A, Graupner V, Lockley M, Balkwill FR, McNeish IA (2010). Abstract 591: Host cell DNA damage and inflammation responses determine oncolytic adenovirus efficacy in ovarian cancer. 591-591.
10.1158/1538-7445.am10-591
Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA(2008). Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene vol. 27, (22) 3081-3090.
10.1038/sj.onc.1210977
Baird SK, Ingemarsdotter CK, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA (2008). Oncolytic adenoviral mutants define a novel mode of programmed cell death in ovarian cancer. HUMAN GENE THERAPY. vol. 19, 399-399.
Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, McNeish IA(2006). Quantifying the activity of adenoviral E1A CR2 deletion mutants using Renilla luciferase bioluminescence and 3 '-deoxy-3 '-[F-18] fluorothymidine positron emission tomography imaging. CANCER RES vol. 66, (18) 9178-9185.
10.1158/0008-5472.CAN-06-1539
Baird SK, Lockley M, Leyton J, Aboagye EO, Lemoine NR, McNeish IA (2006). E1A CR2 deletion mutant adenoviral vectors in ovarian cancer: combination with apoptosis inducers and monitoring with [18F] FLT-PET imaging. CANCER RESEARCH. vol. 66,
Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N, McNeish I(2006). Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res vol. 66, (2) 989-998.
10.1158/0008-5472.CAN-05-2691
McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP, Lemoine NR(2005). Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res vol. 302, (1) 69-82.
10.1016/j.yexcr.2004.08.029
Oakervee HE, Gordon AC, Kaya B, Taussig DC, Lockley M, Barnett MJ, Rohatiner AZS, Lister TA et al. (2002). Outcomes of critical illness in patients with haematological malignancy. BLOOD. vol. 100, 875A-876A.
Return to top